NEXT Financial Group Inc Raises Holdings in Eli Lilly And Co (LLY)

NEXT Financial Group Inc boosted its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 7.8% during the 1st quarter, Holdings Channel reports. The firm owned 8,652 shares of the company’s stock after purchasing an additional 623 shares during the period. NEXT Financial Group Inc’s holdings in Eli Lilly And Co were worth $669,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Private Capital Group LLC grew its position in Eli Lilly And Co by 576.4% during the 1st quarter. Private Capital Group LLC now owns 4,011 shares of the company’s stock worth $310,000 after purchasing an additional 3,418 shares during the last quarter. Garde Capital Inc. purchased a new position in Eli Lilly And Co during the 1st quarter worth $268,000. Sentinel Trust Co. LBA grew its position in Eli Lilly And Co by 100.0% during the 1st quarter. Sentinel Trust Co. LBA now owns 43,357 shares of the company’s stock worth $3,354,000 after purchasing an additional 21,675 shares during the last quarter. Braun Bostich & Associates Inc. purchased a new position in Eli Lilly And Co during the 1st quarter worth $658,000. Finally, Millennium Management LLC boosted its holdings in shares of Eli Lilly And Co by 23.2% in the first quarter. Millennium Management LLC now owns 1,073,495 shares of the company’s stock valued at $83,056,000 after acquiring an additional 202,294 shares in the last quarter. 76.01% of the stock is currently owned by institutional investors.

Get Eli Lilly And Co alerts:

Shares of Eli Lilly And Co opened at $86.82 on Wednesday, according to Marketbeat.com. The company has a quick ratio of 1.01, a current ratio of 1.41 and a debt-to-equity ratio of 0.64. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $89.09. The stock has a market capitalization of $93.47 billion, a P/E ratio of 20.29, a P/E/G ratio of 1.46 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 24th. The company reported $1.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.13 by $0.21. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The firm had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.51 billion. During the same quarter last year, the business earned $0.98 earnings per share. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. research analysts anticipate that Eli Lilly And Co will post 5.15 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be paid a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

Several analysts have recently weighed in on the stock. BMO Capital Markets reaffirmed a “sell” rating and issued a $74.00 target price on shares of Eli Lilly And Co in a report on Wednesday, April 4th. TheStreet downgraded shares of Eli Lilly And Co from a “b” rating to a “c” rating in a report on Monday, March 5th. Barclays set a $98.00 target price on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, May 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, April 18th. Finally, Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Monday, April 9th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus price target of $93.89.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Wednesday, April 25th. The shares were sold at an average price of $80.85, for a total value of $14,553,000.00. Following the completion of the sale, the insider now owns 122,896,904 shares in the company, valued at $9,936,214,688.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Susan Mahony sold 5,165 shares of the firm’s stock in a transaction dated Friday, April 13th. The shares were sold at an average price of $80.14, for a total transaction of $413,923.10. Following the completion of the sale, the senior vice president now owns 45,652 shares of the company’s stock, valued at approximately $3,658,551.28. The disclosure for this sale can be found here. Insiders sold 987,464 shares of company stock valued at $82,748,955 in the last quarter. Company insiders own 0.11% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Leave a Reply

Your email address will not be published. Required fields are marked *